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2014, 251 EU5 gastroenterologists were surveyed regarding their perceptions and 
uptake of sofosbuvir. Additionally, 15 reimbursement-influencing payers were 
interviewed. RESULTS: At the time of surveying, approximately one-quarter of 
treatment-naïve cirrhotic and non-cirrhotic HCV-1 patients in France and Germany 
(where sofosbuvir was then widely available) were on sofosbuvir-based regimens, 
alongside a slightly lower percentage of treatment-experienced such patients, and 
those with HCV-2/3. This speedy uptake reflects sofosbuvir’s high efficacy, which 
previously encouraged physician familiarity via early-access schemes. However, 
interviewed payers insist sustained uptake for large HCV patient populations is 
not viable due to cost, stressing that sofosbuvir be reserved for patients with more 
advanced liver fibrosis or cirrhosis. These payers add that measures such as those 
in France involving treatment caps and a proposal to tax manufacturers when caps 
are exceeded exemplify the innovative cost-containment strategies necessary to 
manage the burden of sofosbuvir. CONCLUSIONS: The EU5 healthcare authorities 
have adapted to include sofosbuvir within their budgets. As indicated by our primary 
research, and confirmed since, creative cost-containment is the order of the day 
across the EU5 for sofosbuvir, with payers forced to reexamine their traditional P&R 
schemes and reevaluate how they define cost-effectiveness. However, such aggres-
sive cost-containment measures have consequences, as demonstrated when thou-
sands took to the streets in Spain in January, 2015, protesting for fairer allocation 
of HCV treatment. Manufacturers of such premium-priced agents may learn from 
Janssen’s negotiations on simeprevir, which offered trade-offs using teleprevir, as 
careful balancing of long-range price expectations and reimbursement and uptake 
potential will be required going forward.
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OBJECTIVES: Misbeliefs regarding vaccine safety and strict immunization exemp-
tion policy have led to anti-vaccination sentiments in West Virginia which might 
affect the vaccination of children. This study assessed the levels of worry and 
hassles towards vaccination and their association with up-to-date vaccination 
status and future intentions to follow recommended vaccinations. METHODS: A 
cross-sectional online survey was conducted among 176 mothers of children under 
3 years old in West Virginia who could read and understand English. Worry and 
hassles scales were developed, and mean scale scores were used to measure worry 
and hassles to vaccination. Chi-square, t-tests and logistic regression analyses 
were conducted. RESULTS: Participants were predominantly white (94.3%), non-
Hispanic Appalachians (98.3%), with annual household income > $50,000 (72.6%) 
and health insurance (92.0%). Approximately 3.8% of participants’ children had not 
received any vaccination. Further, many participants’ children (14.2%) were not up 
to date with recommended vaccinations, and 13.6% of mothers reported no future 
intention to follow recommended vaccination. Chi-square analyses indicated that 
being a full time worker and self or family as child caretaker were associated with 
being up-to-date with recommended vaccination and future intention to follow 
recommended vaccinations (p’s< 0.05). After adjusting for demographic variables, 
hassle scale was a significant predictor of up-to-date vaccination status (AOR 
= 0.12) and future intention to follow recommended vaccinations (AOR = 0.17). 
Similarly, worry scale was a significant predictor of up-to-date vaccination status 
(AOR = 0.24) and future intention to follow recommended vaccinations (AOR = 
0.27). CONCLUSIONS: Despite having higher socio-economic status, many study 
participants’ children exhibited low immunization coverage, and had no future 
intention to follow recommended vaccination. The study highlights the need to 
increase awareness about safety of vaccine contents and its efficacy in preventing 
still endemic diseases like measles.
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OBJECTIVES: The current Ebola Virus outbreak has been responsible for over 5,000 
deaths. This disease, with no effective treatment has a fatality rate around 50%. 
In October, the EMA publically encouraged developers of Ebola treatments and 
vaccines to apply for orphan designation and FDA have already granted orphan 
designation for ZMapp. This research aimed to evaluate the appropriateness of 
utilising the orphan designation as an incentive in these circumstances or whether 
it could actually prove counter-productive. METHODS: A detailed review of EMA and 
FDA orphan designation procedures and the historical context in which they were 
developed were undertaken, alongside a review of the current Ebola treatment and 
vaccinations pipeline. RESULTS: EMA and FDA orphan drug legislation comprise a 
set of incentives for pharmaceutical companies to develop and market medicinal 
products to treat rare diseases, which were being neglected by drug developers due 
to the poor economic potential of such diseases. These include scientific advice, 
fee reductions, access to grants and, most importantly, market exclusivity (7 and 
10 years for the FDA and EMA respectively). However, in contrast to most orphan 
diseases with a lack of pipeline candidates, there are already 7 pipeline drugs for 
Ebola (brincidofovir, favipiravir, ZMapp, TKM-Ebola, AVI-4753, hyperimmune horse 
sera, and BCX4430) and 2 vaccines (ChAd 3, VSV-EBOV). CONCLUSIONS: Granting 
orphan status to pipeline Ebola candidates means that the first-to-market will attain 
market exclusivity in that jurisdiction, such that any later candidates, even if clearly 
more effective, will be prevented from launching until the data exclusivity period 
has expired. This could not only potentially deny Ebola patients in US and Europe 
access to the most efficacious treatments but could also disincentivize companies 
developing potentially more effective therapies. We recommend that the market 
exclusivity aspect of the orphan drug designation should be waived for candidate 
Ebola treatments.
for PILLAR, QUEST-1 and QUEST-2, respectively. Having VR only had a minor posi-
tive impact, and was not statistically significant for most endpoints/trials. Female 
patients had significantly lower values for EQ-5D-VI, and numerically lower values 
for all other QoL-measures. CONCLUSIONS: These findings suggest that short-
term QoL impairment due to HCV-therapy is driven more by the longer duration of 
PR-therapy than by not obtaining VR.
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OBJECTIVES: Limited Patient Reported Outcomes (PRO) data exists for obese 
patients with ABSSSI. This study sought to evaluate health-related quality of life 
(HRQL) in obese patients (BMI > 30) with a positive clinical response (cured, com-
plete resolution of all baseline signs and symptoms and improved, some symp-
toms remain, but no further antibiotics are necessary) patients during an ABSSSI 
trial. METHODS: Adult patients diagnosed with ABSSSI were enrolled in a pro-
spective phase 3, randomized, double-blind study to evaluate antibiotic treatment. 
An analysis of PRO was conducted to understand the difference between cured 
obese patients (COP) and improved obese patients (IOP) with respect to patient 
reported HRQL at End of Treatment (EOT) and late follow up (LFU, study day 21-28). 
HRQL was measured by Extremity Soft Tissue Infection (ESTI) Score[i], a 20 ques-
tion survey using a 5-point Likert scale (5 equals highest degree of importance/
impairment to the patients) measured symptoms, daily functioning, emotional 
functioning, and social interactions. RESULTS: Obese patients compromised 29% 
of the study (660 patients, 589 included in analysis, 193 obese). IOP at EOT were 
less likely to proceed to cure than non-obese patients (26%, 16%) at LFU. The ESTI 
Score was higher at LFU in IOP than COP (46.4, 26.3, p= 0.029). At LFU, IOP were 
more likely than COP to report having continued difficulty performing a job (29.0%, 
9.6%, p= 0.008) and earning an income (32.3%, 14.0%, p= 0.032). CONCLUSIONS: IOP 
had more difficulty than COP with HRQL measures at LFU. IOP at EOT may have 
persistent HRQL issues that require further utilization of health care resources. 
Additional research is needed to determine the potential economic impact of this 
data. [i] Storck et al, Development of a Health-Related Quality of Life Questionnaire 
(HRQL) for patients with Extremity Soft Tissue Infections (ESTI), BMC Infectious 
Diseases 2006, 6:148
INfectIoN – health care use & PolIcy studIes
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OBJECTIVES: The FDA plans to institute a novel regulatory pathway to expedite 
approval of high-need antibiotics, including those for multidrug-resistant gram-
negative pathogens (MDR GNPs). Under this Limited Population Antibacterial Drugs 
(LPAD) approval mechanism, submission of clinical efficacy data from relatively 
small patient populations with high unmet need would be permitted. However, 
drugs approved via this pathway will have limited safety data and likely carry sig-
nificant price premiums over standard-of-care. This study assessed potential mar-
ket access hurdles for LPAD pathway-approved agents providing improvements in 
clinical cure rates, mortality rates and/or length of hospital/ICU stay for infections 
caused by MDR GNPs. METHODS: A total of 30 U.S. hospital pharmacy directors (PDs) 
and 141 U.S hospital-based infectious disease (ID) and non-ID specialists were sur-
veyed regarding their views on reimbursement and likely uptake of LPAD pathway-
approved drugs, assuming these agents cost ≥ $15,000/treatment course. RESULTS: 
Among surveyed physicians and PDs, < 25% and < 50%, respectively, were aware of 
the proposed LPAD pathway. Based on a short explanation, 87% of surveyed PDs 
would include LPAD pathway-approved agents. Among these PDs, 96% would imple-
ment prescribing restrictions on top of those included in the product label, although 
only 27% indicated they would restrict these agents to last-line therapy. Among 
physician respondents, 84% reported that they would use formulary-included LPAD 
pathway-approved agents providing improvements over standard-of-care, with 
agents demonstrating lower mortality rates relative to comparators more likely to 
see uptake. Furthermore, surveyed physicians who would use an LPAD pathway-
approved agent are most likely to do so for the same infections and drug-resistant 
pathogens evaluated during the LPAD process. CONCLUSIONS: Physicians and pay-
ers are receptive to LPAD pathway-approved agents despite potential for safety risks 
and high price premiums. However, prescribing restrictions and price limitations 
are certain among payers, while primary prescribing drivers are improvements in 
clinical cure and mortality rates.
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OBJECTIVES: Sofosbuvir is an indispensable innovation in hepatitis C virus (HCV) 
treatment. However, it has the potential to bust tight EU5 healthcare budgets. 
This study examined early uptake of sofosbuvir, and explored evolving mecha-
nisms in the EU5 used to manage its high cost burden. METHODS: In September 
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importers of antimicrobial medicines are: India (25,8%), Russia (16%), China (9.7%), 
Ukraine (9.7 %), France (6.5 %), and manufacturers from other countries consisted 
- 3,2%. CONCLUSIONS: A large part of the drugs purchased within the guaran-
teed volume of free medical aid in the Republic of Kazakhstan consist from basic 
beta-lactam antibiotics. In the list were presented the outdated drugs (gentamicin), 
which is not recommended for use. Predominant drug are drugs from domestic 
pharmaceutical companies.
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OBJECTIVES: Despite all the control efforts, Malaysia has yet to effectively reduce 
the incidence rate of tuberculosis(TB). TB is not only highly contagious but also 
causing a significant economic burden in the order of USD16 million/year as 
reported by World Health Organization(WHO) in 2014. This study aimed to evalu-
ate the economic impact of TB control in Malaysia using a dynamic transmission 
model. METHODS: Prior to model building, a disease burden study was performed 
in the state of Selangor representing 18% of the Malaysian population. Identified 
patient medical records from public hospitals and clinics were randomly selected 
for study. All direct costs of TB management were captured for analysis. A dynamic 
transmission model was built to project future disease and economic burdens over 
a 10-year period. The study was performed from a government perspective. All costs 
are expressed as USD median (interquartile range). A 3% discount rate was used 
for projections. RESULTS: A total of 436 successfully treated cases were included 
in this study. Of these, 195(44.7%) cases required hospitalisation during treatment 
period. USD616(487-763)/patient was used for non-hospitalisation cases compared 
to USD1,848(1,164-3,284)/patient for those requiring hospitalisation representing 
a 3-fold increase. 119 incomplete treatment cases were selected for comparison. 
USD337(193-902)/patient was used for these incomplete cases. Our model suggests 
that the total TB cases will increase by 65% in 10 years’ time. Using the baseline TB 
population in 2011, an estimated total of USD22.9 million(15.5-37.6 million)/year was 
used for direct medical costs. Based on a local estimated 6.9% incompletion treat-
ment rate, an extra USD5.3 million(3.5-8.6 million)/year (22.9% increase) would be 
required by 2021. CONCLUSIONS: Our findings are consistent with WHO report. In 
Malaysia, hospitalisation appears to be the major cost driver for TB patients receiv-
ing treatment. Healthcare strategies such as early detection, increased awareness of 
TB and improved compliance may potentially reduce TB health budget.
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OBJECTIVES: Differences in vaccine schedules may result in additional costs beyond 
the differences due to pricing variation between two products. There are two oral 
rotavirus vaccines approved for use in Canada; one vaccine is approved as a two-
dose schedule while the other is approved as a three-dose schedule. The objective of 
this study is to explore the cost of administration of a single dose of either rotavirus 
vaccine in each Canadian province as well as for the country overall. METHODS: Two 
extremes were considered: Every dose administered by a physician either (i) requires 
a visit solely for that purpose (cost = administration + visit), or (ii) occurs as part of 
a regular visit (cost = administration only). All costs were derived from the relevant 
fee for service agreement of each province and territory in Canada. Assumptions 
included 90% vaccine coverage across each province’s 2013 birth cohort and no 
significant changes since 2007 to the ratio of physicians to public health nurses 
(PHN) administering vaccines in each province. Delivery by PHN was assumed to 
incur no cost. RESULTS: Scenarios (i) and (ii) above yielded administration costs 
of $6.4M and $600k, respectively, per vaccinated Canadian cohort. Provinces with 
high percentage of physician delivery accounted for the majority of this cost in 
both Scenario (i) (NL: $128.6k, NB: $279.3k, NS: $312.1k, QC: $832.5k, ON: $3.8M, MB: 
$386.3k, BC: $544.1k) and Scenario (ii) (NB: $60.4k, NS: $114.2k, QC: $258.8k, MB: 
$85.1k, BC: $72.8k). CONCLUSIONS: Administration fees can be a costly factor in 
universal immunization schedules. As such, it is essential to account for the differ-
ences in approved administration schedule when evaluating vaccines during the 
assessment of publically funded program implementation.
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OBJECTIVES: Infections caused by multi-drug resistant (MDR) Acinetobacter bau-
mannii (AB) are an increasing global problem. Several studies examining outcomes 
and resource utilization associated with MDRAB have been conducted; however, 
findings are inconsistent. The purpose of this research was to identify and charac-
terize available research concerning resource utilization associated with MDRAB, 
assess strengths and weaknesses of the available research and identify future 
research priorities. METHODS: A systematic review of the literature was conducted 
using MEDLINE and electronically available conference abstracts. Articles were con-
sidered relevant if they reported resource utilization or cost information comparing 
MDRAB patients to controls. Controls could include susceptible AB, other organisms, 
or uninfected patients. RESULTS: Initial searches of the literature returned 204 
potential citations for inclusion. Title and abstract review excluded 171 articles, 
and full-text review excluded 20 additional articles, leaving a total of 13 articles 
eligible for data abstraction and review. Length of stay (LOS) was reported in nine 
PIN94
ProjectINg chaNges IN total days of theraPy (dot) IN PatIeNts 
hosPItalIzed for acute bacterIal skIN aNd skIN structure INfectIoN 
(absssI)
Berger A.1, Kauf T.2, Oster G.3
1Evidera, Lexington, MA, USA, 2Cubist Pharmaceuticals, Lexington, MA, USA, 3Policy Analysis 
Inc. (PAI) and Managing Co-Director, MINERVA Health Economics Network, Brookline, MA, USA
OBJECTIVES: Most patients admitted to hospital for ABSSSI complete antibacte-
rial treatment following discharge. This study examined the potential impact of 
tedizolid versus linezolid on antibacterial DOT, based on real-world inpatient use 
of linezolid in patients hospitalized for ABSSSI, and two pivotal phase 3 studies of 
patients with ABSSSI that demonstrated comparable efficacy and safety between 
a 6-day course of tedizolid (once daily) and a 10-day course of linezolid (twice 
daily). METHODS: Duration of in-hospital therapy for ABSSSI was based on analyses 
of an electronic database containing comprehensive clinical records on ~38 million 
inpatient admissions from > 100 contributing general, acute-care US hospitals. All 
patients aged ≥ 18 years admitted during 2011 with a principal diagnosis consistent 
with ABSSSI who received ≤ 10 inpatient DOT with linezolid were identified. Total 
DOT for linezolid and tedizolid (i.e., inpatient + outpatient) were assumed to be 10 
and 6 days, respectively. Patients receiving < 10 days of in-hospital therapy with lin-
ezolid were assumed to receive the remainder as outpatients; corresponding values 
for tedizolid were estimated assuming a 6-day DOT. Patients receiving ≤ 6 inpatient 
DOT with linezolid were modeled to receive the same number of inpatient days of 
tedizolid; patients with > 6 days of in-hospital therapy with linezolid were modeled 
as completing a course of tedizolid in hospital. RESULTS: Among the 3,734 ABSSSI 
patients who met study entry criteria, 153 (4%) received linezolid. Mean inpatient 
DOT was 3.7 days; consequently, expected duration of outpatient therapy was 6.3 
days. Use of tedizolid instead of linezolid was estimated to reduce average inpatient 
DOT by 0.2 days and outpatient DOT by 3.8 days. CONCLUSIONS: Based on real-
world use of linezolid for ABSSSI and findings from tedizolid pivotal trials, use of 
tedizolid in hospitalized patients with ABSSSI may substantially reduce mean total 
DOT compared with linezolid, primarily on an outpatient basis.
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OBJECTIVES: The objective of this study is to examine the decisive factors associated 
with the use of antiretroviral therapy (ART) among a Human Immunodeficiency 
Virus (HIV) infected population utilizing Andersen’s Behavioral Model. METHODS: 
This study is a retrospective data analysis of individuals infected with HIV in panels 
14 to 16 of the Medical Expenditure Panel Survey in years 2009 to 2012. A logistic 
regression analysis was conducted to evaluate the association between ART usage 
and the factors nested in Andersen’s Behavioral Model, which includes predispos-
ing, enabling and need components. RESULTS: For predisposing characteristics, 
patients taking ART were slightly older (age: 46.14±0.98) than patients not taking 
ART (age: 43.34±0.91). Being a male and African American was highly associated with 
the use of ART, as compared to being a female or white (P value: < 0.0001; 0.00119). 
People living in the Northeast were more likely to take ART than individuals living 
in other regions in the United States (P value: 0.0032). Among enabling components, 
difficulty in receiving medical care and having non-public insurance coverage were 
associated with not taking ART (P value: 0.0851; 0.0013). Having private insurance 
coverage was positively correlated with nonuse of ART (odds ratio: 0.190; 95% CI: 
0.047-0.779; P value: 0.00003). However, family income was not associated with the 
use of ART among the HIV-infected population. With respect to the health status 
in the need component, using ART was associated with reported improved health 
status in general, compared with those not using ART; however, the association was 
not statistically significant. CONCLUSIONS: Predisposing and enabling factors were 
found to be significantly associated with ART usage; however, need factors were not 
found to be significant. More effort is needed to improve the healthcare utilization 
inequality among minority populations.
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OBJECTIVES: Study of drug coverage in the Republic of Kazakhstan as one of the 
most important components of medical care and an important measure of social 
support of citizens. METHODS: The List of drugs for purchase in 2014 by Single 
Distributor “SK-Pharmacy “ was analyzed. The percentage of antimicrobial drugs 
for certain groups of antibiotics and synthetic antibacterial agents of different 
chemical structure was studied. The analysis of drugs from domestic and foreign 
drug manufacturers was performed. RESULTS: Among all antibacterial drugs a big 
part consisted from antibiotics - 71%, synthetic chemotherapeutic drugs amounted 
to 29%. Of the total number of antibiotics the proportion of beta-lactam antibiot-
ics amounted to 61,36%, macrolides and azalides – to 15,91%, aminoglycoside – to 
6,82%, tetracyclines and glycopeptides to 2,27%, antibiotics from other groups - 
to11,36%. Among beta-lactam antibiotics a big part consisted from semisynthetic 
penicillins with wide spectrum - 29.6%, mainly amoxicillin and its “secured forms”. 
Cephalosporins consisted 51.85% of the total number of antibiotics, and were bought 
mainly drugs of 3rd generation. Carbapenems amounted to 11.11%, monobactams 
were not bought. From the group of aminoglycosides following drugs were bought: 
amikacin, kanamycin, streptomycin, gentamicin. Synthetic antibacterial drugs of 
different chemical structures were represented mainly by fluoroquinolones (66,67%): 
moxifloxacin, ofloxacin, norfloxacin, pefloxacin , ciprofloxacin. The half (50%) of 
procured medicines are products of domestic pharmaceutical companies. The main 
